+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      Dopaminergic Regulation of Glandular Kallikrein in the Intermediate Lobe of the Rat Pituitary


      S. Karger AG

      Bromocriptine, Endorphins, Precursor processing, Pituitary gland, Kallikrein, Dopamine, Reserpine, Haloperidol

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          The intermediate lobe of the rat pituitary contains a trypsin-like protease closely related or identical to glandular kallikrein. This study examined whether glandular kallikrein in the intermediate lobe is under inhibitory control by dopaminergic systems. Male rats were treated for 4–6 days with various doses of the following drugs, alone or in combination: haloperidol (a dopamine receptor blocker), reserpine (a catecholamine depleting agent), and bromocriptine (a dopamine receptor agonist). Neurointermediate lobe () homogenates were prepared. Following activation of latent enzymes with tryspin, glandular kallikrein was measured using two chromogenic peptide substrates. Haloperidol doubled glandular kallikrein activity. Dissection of the revealed that haloperidol specifically increased glandular kallikrein in the intermediate lobe and had no effect on the small amount of activity in the neural lobe. Reserpine also doubled glandular kallikrein and haloperidol did not produce further increases. The reserpine-induced increase in glandular kallikrein was completely blocked by concurrent administration of bromocriptine: this effect was blocked by haloperidol. The results demonstrate that intermediate lobe glandular kallikrein is under inhibitory control by dopaminergic systems. This parallels the regulation of proopiomelanocortin (POMC) synthesis in the intermediate lobe and suggests that glandular kallikrein should be evaluated as a POMC-processing enzyme.

          Related collections

          Author and article information

          S. Karger AG
          01 April 2008
          : 43
          : 3
          : 368-376
          Department of Pharmacology, New York Medical College, Valhalla, N.Y., USA
          124564 Neuroendocrinology 1986;43:368–376
          © 1986 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 9
          Original Paper


          Comment on this article